Fig. 5

In vivo effects of rivoceranib in the xenograft model. A The mean LMeC tumour volumes in the four groups (vehicle and 75 mg/kg, 150 mg/kg, and 300 mg/kg rivoceranib-treated; n = 10 in each group), and images of the collected tumours from the xenograft models after 29 days of treatment. B The mean CHMp tumour volumes in the four groups (vehicle and 75 mg/kg, 150 mg/kg, and 300 mg/kg rivoceranib-treated; n = 10 in each group), and images of the collected tumours from the xenograft models after 16 days of treatment. C The tumour weights and D body weights of mice were monitored twice a week during rivoceranib treatment in both cell lines. The data represent the mean ± standard deviation * p < 0.05, ** p < 0.01